Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

ABSTRACT: The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐risk chronic myelomonocytic leukemia (higher‐risk CMML), or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Transl Sci
Autors principals: Zhou, Xiaofei, Friedlander, Sharon, Kupperman, Erik, Sedarati, Farhad, Kuroda, Shingo, Hua, Zhaowei, Yuan, Ying, Yamamoto, Yuka, Faller, Douglas V., Haikawa, Kazue, Nakai, Katsuhiko, Bowen, Sharon, Dai, Yi, Venkatakrishnan, Karthik
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212745/
https://ncbi.nlm.nih.gov/pubmed/33503305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12972
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars